gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Germ Cell Tumours of the Central Nervous System – a multidisciplinary team approach

Meeting Abstract

  • corresponding author presenting/speaker Gabriele Calaminus - University Hospitals, Duesseldorf, Düsseldorf, Deutschland
  • J. Nicholson - University Hospitals, Cambridge
  • D. Frappaz - University Hospitals, Lyon
  • M.L. Garre - University Hospitals, Genova
  • R. Kortmann - University Hospitals, Leipzig
  • C. Alapetite - Institute Curie, Paris
  • U. Ricardi - University Hospitals, Turin
  • F. Saran - Royal Marsden, London
  • U. Göbel - University Hospitals, Duesseldorf

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocIS020

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk020.shtml

Veröffentlicht: 20. März 2006

© 2006 Calaminus et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Intracranial germ cell tumours (GCTs) are rare and predominantly diagnosed between the age of 6 and 14 years in males. They are typically midline tumours of the suprasellar or pineal region. They present with raised intracranial pressure, endocrinological and opthalmological impairment. Diagnosis is based on: clinical symptoms, markers in serum and CSF, neuroimaging, cytological (CSF) and histological confirmation. The elevation of AFP in serum/ CSF (> 25 ng/ml) is typical for a yolk sac tumor component and ß-HCG (> 50 IU/L) for the appearance of a choriocarcinoma. All these aspects are strongly recommended to be examined by a multidisciplinary team (neurosurgeon, oncologist, neuro-radiologist, pathologist) before treatment (including surgery) is started . It is essential to try to perform the correct staging and diagnosis before treatment decisions are made because this can positively influence the results of therapy and outcome. About 25% of all pediatric CNS GCT present as tumors with more than one histology. Histological types are: germinoma and non-germinoma, such as yolk sac tumors, choriocarcinoma, embryonal carcinoma and as so called benign tumors; teratoma. Therapy and prognosis depend on the component with the highest malignancy and on dissemination. It can be expected that about 15% of the germinoma and 20% of the non-germinomatous tumors are metastatic. Bifocal disease appear in about 20% and are treated as non-metastatic. Within the last 20 years craniospinal (CS) irradiation (RT) has been the treatment in Germinoma. With 30 to 24 Gy to the CS axis and a tumor boost between 20 and 16 Gy it is possible to cure about 90% of the patients. The other attempt to treat germinoma is chemotherapy (Carbo-PEI) and local RT (non-metastatic). With this approach survival rates are about 85%. In non-germinoma a combined treatment with Cisplatin as the leading agent is used (PEI) in combination with focal RT or CS RT in respect to dissemination. Event-free survival is around 70%. Incomplete staging is a major risk factor in germinoma. With combined treatment and focal RT mainly ventricular relapses are diagnosed. AFP-level at diagnosis may play an important role for prognosis of non-germinoma. Analysis within the SIOP CNS GCT protocol reveals a prognostic impact of a tumor residue after the end of treatment. In the fourthcoming SIOP CNS GCT II protocol these findings will be addressed. Supported in part by Deutsche Krebshilfe